A Phase 1/2 interventional study of Botulinum toxin type A in Glabellar Frown Lines, sponsored by ATGC Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-09.
Sponsored by ATGC Co., Ltd. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Efficacy and safety of the investigational product, ATGC-110, was evaluated in comparison with Botox for a total of 12 weeks after the administration in treatment of glabellar frown lines.
ATGC Co., Ltd. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects who have received other procedures that may affect the assessment of the glabellar or forehead lines during the following periods:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Botulinum toxin type A
Drug: Botulinum toxin type A
Total of 20U/0.5mL is intramuscularly administered to five points of the glabellar region, 4U/0.1mL each
Glabellar line improvement rate at maximum frown confirmed with investigator's live assessment
Changes in the glabellar line severity at maximum frown from baseline to 4 weeks after the IP administration were evaluated by investigator
Time frame: 0 and 4 weeks after the administration
Glabellar line improvement rate at maximum frown confirmed by investigator's live assessment
Changes in the glabellar line severity at maximum frown from baseline to 8 and 12 weeks after the IP administration were evaluated by investigator
Time frame: 0, 8, 12 weeks after the administration
Glabellar line improvement rate at rest confirmed by investigator's live assessment
Changes in the glabellar line severity at rest from baseline to 4, 8 and 12 weeks after the IP administration were evaluated by investigator
Time frame: 0, 4, 8, 12 weeks after the administration
Glabellar line improvement rate at rest confirmed by subject's assessment
Changes in the glabellar line severity at rest from baseline to 4, 8 and 12 weeks after the IP administration were evaluated by subjects
Time frame: 0, 4, 8, 12 weeks after the administration
Subject satisfaction rate
Subjects fill out the satisfaction questionnaire
Time frame: 0, 4, 8, 12 weeks after the administration
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2019 to primary completion in Apr 2020, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A
ATGC Co., Ltd.